Certified by Founder Lodge
CellCentric
United Kingdom - Cambridge
START UP
1 Disclosed Funding Rounds $25,000,000
0 Participating Investments
-
Founded date
2004
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.
p300/CBP are twin (paralogue) acetyl transferases
Pfizer
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
Scorability | $11,000,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
